You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePethidine
Accession NumberDB00454  (APRD00074)
TypeSmall Molecule
GroupsApproved
DescriptionA narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. [PubChem]
Structure
Thumb
Synonyms
Isonipecaïne
Meperidine
Pethidin
Péthidine
Pethidine dbl
Pethidinum
Petidina
Petydyna
Sauteralgyl
Spasmedal
Spasmodolin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Demerolinjection, solution100 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demeroltablet50 mg/1oralSanofi Aventis U.S. Llc1942-11-10Not applicableUs
Demerolinjection, solution50 mg/mLintramuscular; intravenous; subcutaneousPhysicians Total Care, Inc.2007-08-21Not applicableUs
Demerolinjection, solution100 mg/2mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution75 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution25 mg/.5mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demeroltablet100 mg/1oralSanofi Aventis U.S. Llc1942-11-10Not applicableUs
Demeroltablet50 mg/1oralbryant ranch prepack2013-04-01Not applicableUs
Demerolinjection, solution100 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution100 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution50 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution25 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demeroltablet50 mgoralSanofi Aventis Canada Inc1944-12-31Not applicableCanada
Demerolinjection, solution50 mg/mLintramuscular; intravenous; subcutaneousPhysicians Total Care, Inc.1994-04-11Not applicableUs
Demerolinjection, solution50 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution75 mg/1.5mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution50 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.1942-11-10Not applicableUs
Demerolinjection, solution100 mg/mLintramuscular; intravenous; subcutaneousPhysicians Total Care, Inc.2003-03-11Not applicableUs
Demerol 50mg - Liq Im IV Sc 50mg/mlliquid50 mgintramuscular; intravenous; subcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 50mg - Liq Im Sc 50mg/mlliquid50 mgintramuscular; subcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 10%-liq Im IV Scliquid100 mgintramuscular; intravenous; subcutaneousSanofi Canada, Inc.1944-12-312001-08-10Canada
Demerol 10%-liq Im Sc 100mg/mlliquid100 mgintramuscular; subcutaneousSanofi Canada, Inc.1944-12-312001-08-17Canada
Demerol 100 mg/mlsolution100 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation2000-08-15Not applicableCanada
Demerol 100 mg/mlsolution100 mgintramuscular; subcutaneousHospira Healthcare Corporation2000-05-01Not applicableCanada
Demerol 50 mg/ml (multiple Dose With Metacresol As Preservative)solution50 mgintramuscular; subcutaneousHospira Healthcare Corporation2000-12-012012-08-03Canada
Demerol 50 mg/ml (single Use, Preservative Free)solution50 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation2000-12-01Not applicableCanada
Demerol 75 mg/mlsolution75 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation2000-12-01Not applicableCanada
Demerol 75mg - Liq Im IV Sc 75mg/mlliquid75 mgintramuscular; intravenous; subcutaneousSanofi Canada, Inc.1969-12-312001-08-10Canada
Meperidine HCl Injection 100mg/mlsolution100 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 10mg/mlsolution10 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 25mg/mlsolution25 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 50mg/mlsolution50 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine HCl Injection 75mg/mlsolution75 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Meperidine Hydrochloride Injection 10mg/ml USPsolution10 mgintravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPsolution75 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPsolution50 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Meperidine Hydrochloride Injection USPsolution100 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1988-12-31Not applicableCanada
Pethidine Injection B.P.solution10 mgintravenousHospira Healthcare Corporation1998-09-242012-08-03Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meperidine Hydrochloridetablet100 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2007-01-04Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralBarr Laboratories Inc.2015-02-24Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralMikart, Inc.2009-06-24Not applicableUs
Meperidine Hydrochloridesolution50 mg/5mLoralRoxane Laboratories, Inc1985-01-30Not applicableUs
Meperidine Hydrochlorideinjection50 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine Hydrochlorideinjection, solution10 mg/mLintravenousHospira, Inc.1984-08-16Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralPhysicians Total Care, Inc.2009-09-14Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralbryant ranch prepack1998-12-17Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralQualitest Pharmaceuticals1998-12-17Not applicableUs
Meperidine Hydrochloridetablet75 mg/1oralMikart, Inc.2009-06-24Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralRoxane Laboratories, Inc1997-03-12Not applicableUs
Meperidine Hydrochlorideinjection100 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralBarr Laboratories Inc.1997-02-03Not applicableUs
Meperidine Hydrochlorideinjection50 mg/mLintramuscularPhysicians Total Care, Inc.2010-03-04Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralQualitest Pharmaceuticals1998-12-17Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralMikart, Inc.2009-06-24Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralRoxane Laboratories, Inc1997-03-12Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralEpic Pharma, LLC2011-05-05Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2007-01-04Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralBarr Laboratories Inc.1996-10-11Not applicableUs
Meperidine Hydrochlorideinjection25 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1975-01-22Not applicableUs
Meperidine Hydrochloridetablet150 mg/1oralMikart, Inc.2009-06-24Not applicableUs
Meperidine Hydrochloridetablet50 mg/1oralRoxane Laboratories, Inc1997-03-12Not applicableUs
Meperidine Hydrochloridetablet100 mg/1oralEpic Pharma, LLC2011-05-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meperidine HClinjection, solution10 mg/mLintravenousCantrell Drug Company2012-01-23Not applicableUs
International Brands
NameCompany
Dolantinsanofi-aventis
Dolcontralmibe
DolosalCristália
DolsinBiotika
LydolSopharma
MialginZentiva
PetidinNycomed
Brand mixtures
NameLabellerIngredients
Meperidine Hydrochloride and Promethazine HydrochlorideEci Pharmaceuticals Llc
Salts
Name/CASStructureProperties
Meperidine hydrochloride
ThumbNot applicableDBSALT001046
Pethidine hydrochloride
Thumb
  • InChI Key: WCNLCIJMFAJCPX-UHFFFAOYSA-N
  • Monoisotopic Mass: 283.13390666
  • Average Mass: 283.794
DBSALT000628
Categories
UNII9E338QE28F
CAS number57-42-1
WeightAverage: 247.3327
Monoisotopic: 247.157228921
Chemical FormulaC15H21NO2
InChI KeyInChIKey=XADCESSVHJOZHK-UHFFFAOYSA-N
InChI
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
IUPAC Name
ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
SMILES
CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylacetate
  • Piperidinecarboxylic acid
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to control moderate to severe pain.
PharmacodynamicsMeperidine is a synthetic opiate agonist belonging to the phenylpiperidine class. Meperidine may produce less smooth muscle spasm, constipation, and depression of the cough reflex than equivalent doses of morphine. The onset of action is lightly more rapid than with morphine, and the duration of action is slightly shorter. The chemical structure of meperidine is similar to local anesthetics. Meperidine is recommended for relief of moderate to severe acute pain and has the unique ability to interrupt postoperative shivering and shaking chills induced by amphotericin B. Meperidine has also been used for intravenous regional anesthesia, peripheral nerve blocks and intraarticular, epidural and spinal analgesia. Meperidine is considered a second-line agent for the treatment of acute pain.
Mechanism of actionMeperidine is primarily a kappa-opiate receptor agonist and also has local anesthetic effects. Meperidine has more affinity for the kappa-receptor than morphine. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Related Articles
AbsorptionThe oral bioavailability of meperidine in patients with normal hepatic function is 50-60% due to extensive first-pass metabolism. Bioavailability increases to 80-90% in patients with hepatic impairment (e.g. liver cirrhosis). Meperidine is less than half as effective when administered orally compared to parenteral administration. One study reported that 80-85% of the drug administered intramuscularly was absorbed within 6 hours of intragluteal injection in health adults; however, inter-individual variation and patient-specific variable appear to cause considerable variations in absorption upon IM injection.
Volume of distribution

Meperidine crosses the placenta and is distributed into breast milk.

Protein binding60-80% bound to plasma proteins, primarily albumin and α1-acid glycoprotein. The presence of cirrhosis or active viral hepatitis does not appear to affect the extent of protein binding.
Metabolism

Meperidine is metabolized in the liver by hydrolysis to meperidinic acid followed by partial conjugation with glucuronic acid. Meperidine also undergoes N-demethylation to normeperidine, which then undergoes hydrolysis and partial conjugation. Normeperidine is about half as potent as meperidine, but it has twice the CNS stimulation effects.

Route of eliminationExcreted in the urine. The proportion of drug that is excreted unchanged or as metabolites is dependent on pH. When urine pH is uncontrolled, 5-30% of the meperidine dose is excreted as normeperidine and approximately 5% is excreted unchanged. Meperidine and normeperidine are found in acidic urine, while the free and conjugated forms of meperidinic and normperidinic acids are found in alkaline urine.
Half lifeInitial distribution phase (t1/2 α) = 2-11 minutes; terminal elimination phase (t1/2 β) = 3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t1/2 β is prolonged to 7-11 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9947
Blood Brain Barrier+0.9876
Caco-2 permeable+0.6683
P-glycoprotein substrateSubstrate0.7821
P-glycoprotein inhibitor IInhibitor0.5174
P-glycoprotein inhibitor IIInhibitor0.5401
Renal organic cation transporterInhibitor0.6375
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateSubstrate0.8826
CYP450 3A4 substrateSubstrate0.5073
CYP450 1A2 substrateNon-inhibitor0.6897
CYP450 2C9 inhibitorNon-inhibitor0.6691
CYP450 2D6 inhibitorInhibitor0.7415
CYP450 2C19 inhibitorNon-inhibitor0.7635
CYP450 3A4 inhibitorNon-inhibitor0.6876
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5547
Ames testNon AMES toxic0.8694
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.9145
Rat acute toxicity3.1526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8593
hERG inhibition (predictor II)Inhibitor0.5813
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Sanofi aventis us llc
  • Abbott laboratories pharmaceutical products div
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Elkins sinn div ah robins co inc
  • International medication systems ltd
  • Parke davis div warner lambert co
  • Watson laboratories inc
  • International medication system
  • Mallinckrodt chemical inc
  • Roxane laboratories inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mallinckrodt inc
  • Mikah pharma llc
  • Mikart inc
  • Mutual pharmaceutical co inc
  • Vintage pharmaceuticals inc
  • Wyeth ayerst laboratories
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous; subcutaneous100 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous100 mg/2mL
Injection, solutionintramuscular; intravenous; subcutaneous25 mg/.5mL
Injection, solutionintramuscular; intravenous; subcutaneous25 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous50 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous75 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous75 mg/1.5mL
Tabletoral100 mg/1
Tabletoral50 mg/1
Tabletoral50 mg
Liquidintramuscular; intravenous; subcutaneous50 mg
Liquidintramuscular; subcutaneous50 mg
Liquidintramuscular; intravenous; subcutaneous100 mg
Liquidintramuscular; subcutaneous100 mg
Solutionintramuscular; intravenous; subcutaneous100 mg
Solutionintramuscular; subcutaneous100 mg
Solutionintramuscular; subcutaneous50 mg
Solutionintramuscular; intravenous; subcutaneous50 mg
Solutionintramuscular; intravenous; subcutaneous75 mg
Liquidintramuscular; intravenous; subcutaneous75 mg
Solutionintramuscular; intravenous; subcutaneous10 mg
Solutionintramuscular; intravenous; subcutaneous25 mg
Injectionintramuscular50 mg/mL
Injectionintramuscular; intravenous; subcutaneous100 mg/mL
Injectionintramuscular; intravenous; subcutaneous25 mg/mL
Injectionintramuscular; intravenous; subcutaneous50 mg/mL
Injection, solutionintravenous10 mg/mL
Solutionoral50 mg/5mL
Tabletoral150 mg/1
Tabletoral75 mg/1
Capsuleoral
Solutionintravenous10 mg
Prices
Unit descriptionCostUnit
Meperidine HCl 100 mg/ml vial33.99USD vial
Meperidine hcl powder10.51USD g
Demerol 100 mg tablet3.33USD tablet
Demerol 100 mg/ml vial1.79USD ml
Demerol 50 mg tablet1.71USD tablet
Meperidine HCl 100 mg tablet1.33USD tablet
Meperidine 100 mg tablet1.31USD tablet
Demerol 100 mg/ml ampul1.1USD ml
Meperidine Hydrochloride 100 mg/ml1.1USD ml
Meperidine Hydrochloride 75 mg/ml1.04USD ml
Meperidine Hydrochloride 50 mg/ml0.98USD ml
Meperidine HCl 50 mg tablet0.93USD tablet
Demerol 50 mg/ml vial0.85USD ml
Meperidine 10 mg/ml syringe0.85USD ml
Meperidine 50 mg tablet0.69USD tablet
Demerol 50 mg/ml ampul0.58USD ml
Meperidine 10 mg/ml cartrdge0.3USD ml
Demerol 50 mg Tablet0.16USD tablet
Meperidine HCl 50 mg/5ml Solution0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility3220 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.72SANGSTER (1994)
logS-1.89ADME Research, USCD
pKa8.59SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.11 mg/mLALOGPS
logP2.9ALOGPS
logP2.46ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.48 m3·mol-1ChemAxon
Polarizability28.09 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9620000000-7309f4ee3918ea05f00dView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02AB02N02AG03N02AB52N02AB72
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (173 KB)
MSDSDownload (6.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pethidine.
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Pethidine.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pethidine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Pethidine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Pethidine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Pethidine.
AbirateroneThe metabolism of Pethidine can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Pethidine.
AcepromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Acetophenazine.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pethidine.
adipiplonThe risk or severity of adverse effects can be increased when Pethidine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Pethidine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Pethidine.
AlmotriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Almotriptan.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Pethidine.
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Pethidine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pethidine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pethidine.
AlvimopanThe risk or severity of adverse effects can be increased when Pethidine is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amiloride.
AmiodaroneThe metabolism of Pethidine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Pethidine which could result in a higher serum level.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Amobarbital.
AmoxapinePethidine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pethidine.
AmperozideThe risk or severity of adverse effects can be increased when Pethidine is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Pethidine.
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Pethidine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pethidine.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Pethidine.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Pethidine.
AprepitantThe serum concentration of Pethidine can be increased when it is combined with Aprepitant.
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Pethidine.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Pethidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.
ArmodafinilThe metabolism of Pethidine can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Pethidine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Asenapine.
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Pethidine.
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Pethidine.
AtomoxetineThe metabolism of Pethidine can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pethidine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pethidine.
AzaperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Azaperone.
AzelastinePethidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pethidine.
AzosemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Pethidine is combined with Baclofen.
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
BarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Barbital.
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Pethidine.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pethidine.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pethidine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Pethidine.
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Pethidine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pethidine.
BenzocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Pethidine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzyl alcohol.
BetaxololThe metabolism of Pethidine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Pethidine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Pethidine is combined with Bifeprunox.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pethidine.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Pethidine.
BortezomibThe metabolism of Pethidine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pethidine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
BrimonidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pethidine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Pethidine.
BuprenorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Buprenorphine.
BupropionThe metabolism of Pethidine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pethidine.
ButacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Pethidine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Pethidine is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Pethidine.
ButorphanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pethidine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pethidine.
Canrenoic acidThe risk or severity of adverse effects can be increased when Pethidine is combined with Canrenoic acid.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pethidine.
CarbamazepineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Pethidine is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the serotonergic activities of Pethidine.
CelecoxibThe metabolism of Pethidine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Pethidine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Pethidine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloroprocaine.
ChloroquineThe metabolism of Pethidine can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pethidine.
ChlorphentermineChlorphentermine may increase the analgesic activities of Pethidine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Pethidine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Pethidine can be decreased when combined with Cholecalciferol.
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Pethidine.
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Pethidine.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.
CimetidineThe serum concentration of Pethidine can be increased when it is combined with Cimetidine.
CinacalcetThe metabolism of Pethidine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cinchocaine.
CitalopramPethidine may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Pethidine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Pethidine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Pethidine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Pethidine is combined with Clidinium.
ClobazamThe metabolism of Pethidine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Pethidine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with clomethiazole.
ClomipraminePethidine may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Pethidine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonidine.
ClopidogrelThe metabolism of Pethidine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Pethidine is combined with Clorazepate.
ClotrimazoleThe metabolism of Pethidine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clozapine.
ClozapineThe metabolism of Pethidine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Pethidine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pethidine.
ConivaptanThe serum concentration of Pethidine can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Conivaptan.
CrizotinibThe metabolism of Pethidine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pethidine.
CyclosporineThe metabolism of Pethidine can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyproheptadine.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.
DabrafenibThe serum concentration of Pethidine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pethidine.
DapoxetinePethidine may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pethidine.
DarunavirThe serum concentration of Pethidine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Pethidine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Pethidine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Pethidine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Pethidine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Desflurane.
DesipramineThe metabolism of Pethidine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pethidine.
DesmopressinThe risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Detomidine.
DexamethasoneThe serum concentration of Pethidine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pethidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexmedetomidine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Pethidine.
DextromethorphanThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.
DifenoxinThe risk or severity of adverse effects can be increased when Pethidine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Pethidine can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydromorphine.
DiltiazemThe metabolism of Pethidine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Pethidine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Pethidine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenoxylate.
DolasetronDolasetron may increase the serotonergic activities of Pethidine.
DoramectinThe risk or severity of adverse effects can be increased when Pethidine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Pethidine is combined with Doxepin.
DoxorubicinThe metabolism of Pethidine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Pethidine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
DoxylamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Pethidine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
DronedaroneThe metabolism of Pethidine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Pethidine is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Drotebanol.
DuloxetineThe metabolism of Pethidine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Pethidine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Pethidine.
EcgonineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pethidine is combined with ECGONINE METHYL ESTER.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Pethidine.
EfavirenzThe serum concentration of Pethidine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Pethidine is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efonidipine.
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Pethidine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pethidine.
EliglustatThe metabolism of Pethidine can be decreased when combined with Eliglustat.
EluxadolinePethidine may increase the constipating activities of Eluxadoline.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pethidine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine.
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Pethidine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pethidine.
EntacaponeThe risk or severity of adverse effects can be increased when Pethidine is combined with Entacapone.
EnzalutamideThe serum concentration of Pethidine can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Eplerenone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergotamine.
ErythromycinThe metabolism of Pethidine can be decreased when combined with Erythromycin.
EscitalopramPethidine may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pethidine.
Eslicarbazepine acetateThe serum concentration of Pethidine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Pethidine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pethidine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.
EthanolPethidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pethidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pethidine.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pethidine.
EthosuximideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pethidine.
EtoperidonePethidine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etorphine.
EtravirineThe serum concentration of Pethidine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Pethidine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fencamfamine.
FenfluraminePethidine may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Pethidine is combined with Fentanyl.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.
FexofenadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Pethidine is combined with Flibanserin.
FluconazoleThe metabolism of Pethidine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunitrazepam.
FluoxetinePethidine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Pethidine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Pethidine.
FluphenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluticasone Propionate.
FluvoxaminePethidine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Pethidine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Pethidine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pethidine can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.
FosphenytoinThe serum concentration of Pethidine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Pethidine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Pethidine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Pethidine.
FurosemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.
Fusidic AcidThe serum concentration of Pethidine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Pethidine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pethidine is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pethidine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pethidine is combined with Gamma Hydroxybutyric Acid.
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Pethidine.
GemfibrozilThe metabolism of Pethidine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Pethidine is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pethidine.
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Pethidine.
GranisetronGranisetron may increase the serotonergic activities of Pethidine.
GuanfacineThe risk or severity of adverse effects can be increased when Pethidine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Pethidine is combined with Haloperidol.
HaloperidolThe metabolism of Pethidine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Pethidine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Pethidine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pethidine.
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Hexobarbital.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Pethidine.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pethidine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Pethidine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Pethidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pethidine.
IdelalisibThe serum concentration of Pethidine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Iloperidone.
ImatinibThe metabolism of Pethidine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Pethidine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Imipramine.
IndalpinePethidine may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.
IndinavirThe metabolism of Pethidine can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.
IproclozideIproclozide may increase the serotonergic activities of Pethidine.
IproniazidIproniazid may increase the serotonergic activities of Pethidine.
IsavuconazoniumThe metabolism of Pethidine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Pethidine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Pethidine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Isoflurane.
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pethidine.
IsoniazidThe metabolism of Pethidine can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Pethidine is combined with Isosorbide.
IsradipineThe metabolism of Pethidine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Pethidine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Pethidine can be increased when it is combined with Ivacaftor.
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Pethidine.
KetamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketobemidone.
KetoconazoleThe metabolism of Pethidine can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Pethidine is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lamotrigine.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.
LevetiracetamThe risk or severity of adverse effects can be increased when Pethidine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Pethidine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomethadyl Acetate.
LevomilnacipranPethidine may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pethidine.
LevorphanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pethidine.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Pethidine.
LinezolidThe risk or severity of adverse effects can be increased when Pethidine is combined with Linezolid.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Pethidine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.
LithiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Lofentanil.
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.
LoratadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pethidine.
LorcaserinThe metabolism of Pethidine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Pethidine is combined with Lorcaserin.
LovastatinThe metabolism of Pethidine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Loxapine.
Lu AA21004Pethidine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Pethidine.
LuliconazoleThe serum concentration of Pethidine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pethidine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Pethidine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pethidine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Pethidine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Pethidine is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Pethidine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.
MeclizineThe risk or severity of adverse effects can be increased when Pethidine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Pethidine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Pethidine.
MepivacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.
MersalylThe risk or severity of adverse effects can be increased when Pethidine is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Pethidine.
MesoridazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.
MethadoneThe metabolism of Pethidine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pethidine is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Pethidine.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pethidine.
MethapyrileneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
MethohexitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Pethidine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the serotonergic activities of Pethidine.
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Pethidine.
MetoclopramideThe risk or severity of adverse effects can be increased when Pethidine is combined with Metoclopramide.
MetolazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.
MetoprololThe metabolism of Pethidine can be decreased when combined with Metoprolol.
MetyrosinePethidine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.
MifepristoneThe metabolism of Pethidine can be decreased when combined with Mifepristone.
MilnacipranPethidine may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pethidine.
MinaprineMinaprine may increase the serotonergic activities of Pethidine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
MirabegronThe metabolism of Pethidine can be decreased when combined with Mirabegron.
MirtazapinePethidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pethidine.
MitotaneThe serum concentration of Pethidine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the serotonergic activities of Pethidine.
MoclobemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Moclobemide.
ModafinilThe serum concentration of Pethidine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.
MolindoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Pethidine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pethidine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Pethidine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Pethidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
NabiloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Nabilone.
NafcillinThe serum concentration of Pethidine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Pethidine.
NalbuphineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Pethidine can be decreased when used in combination with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Naratriptan.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Pethidine.
NefazodoneThe metabolism of Pethidine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Nefazodone.
NelfinavirThe metabolism of Pethidine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Pethidine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pethidine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Pethidine.
NicardipineThe metabolism of Pethidine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Pethidine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Pethidine.
OctamoxinOctamoxin may increase the serotonergic activities of Pethidine.
OlanzapinePethidine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine.
OlaparibThe metabolism of Pethidine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olopatadine.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pethidine.
OmeprazoleThe metabolism of Pethidine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Pethidine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Pethidine.
OpiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Opium.
OrphenadrinePethidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pethidine.
OsanetantThe risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant.
OsimertinibThe serum concentration of Pethidine can be increased when it is combined with Osimertinib.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Pethidine.
OxazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pethidine.
OxycodoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pethidine.
PalbociclibThe serum concentration of Pethidine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Pethidine.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pethidine.
PanobinostatThe metabolism of Pethidine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pethidine can be decreased when combined with Pantoprazole.
ParaldehydePethidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pethidine.
PargylinePargyline may increase the serotonergic activities of Pethidine.
ParoxetinePethidine may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Pethidine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pethidine.
PentazocinePentazocine may decrease the analgesic activities of Pethidine.
PentazocineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pethidine.
PerampanelThe risk or severity of adverse effects can be increased when Pethidine is combined with Perampanel.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pethidine.
PerospironeThe risk or severity of adverse effects can be increased when Pethidine is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Pethidine.
PerphenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenelzine.
PheniprazinePheniprazine may increase the serotonergic activities of Pethidine.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenoxyethanol.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Pethidine.
PhenterminePhentermine may increase the analgesic activities of Pethidine.
PhenytoinThe serum concentration of Pethidine can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenytoin.
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Pethidine.
PimozideThe risk or severity of adverse effects can be increased when Pethidine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.
PipotiazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pethidine.
PiretanideThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.
PirlindolePirlindole may increase the serotonergic activities of Pethidine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Pethidine.
PizotifenThe risk or severity of adverse effects can be increased when Pethidine is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.
PosaconazoleThe metabolism of Pethidine can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.
PramipexolePethidine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pethidine.
PrilocaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prilocaine.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PrimidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Primidone.
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Pethidine.
ProcaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Procarbazine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Pethidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pethidine.
PromazinePromazine may increase the hypotensive activities of Pethidine.
PromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Pethidine.
PromethazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pethidine.
ProparacaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Pethidine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Pethidine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Pethidine is combined with PSD502.
QuazepamThe serum concentration of Pethidine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.
QuinethazoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pethidine.
QuinineThe metabolism of Pethidine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Pethidine is combined with Ramelteon.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pethidine.
RamosetronPethidine may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Pethidine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Pethidine.
RasagilineThe risk or severity of adverse effects can be increased when Pethidine is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Remifentanil.
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Pethidine.
RemoxiprideThe risk or severity of adverse effects can be increased when Pethidine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Pethidine is combined with Reserpine.
RifabutinThe metabolism of Pethidine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pethidine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Pethidine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Pethidine.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Pethidine.
RizatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Rizatriptan.
RolapitantThe metabolism of Pethidine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Romifidine.
RopinirolePethidine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Pethidine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine.
RotigotinePethidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pethidine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pethidine is combined with S-Ethylisothiourea.
SafrazineSafrazine may increase the serotonergic activities of Pethidine.
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Pethidine.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Pethidine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pethidine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pethidine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
SecobarbitalThe risk or severity of adverse effects can be increased when Pethidine is combined with Secobarbital.
SelegilineSelegiline may increase the serotonergic activities of Pethidine.
SelegilineThe risk or severity of adverse effects can be increased when Pethidine is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Pethidine is combined with Sertindole.
SertralinePethidine may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Pethidine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Pethidine is combined with Sevoflurane.
SildenafilThe metabolism of Pethidine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Pethidine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pethidine can be increased when it is combined with Simeprevir.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Pethidine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Pethidine is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pethidine.
SorafenibThe metabolism of Pethidine can be decreased when combined with Sorafenib.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pethidine.
SpironolactoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Spironolactone.
St. John's WortThe serum concentration of Pethidine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Pethidine is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Pethidine.
SufentanilThe risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.
SulfisoxazoleThe metabolism of Pethidine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Pethidine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Sumatriptan.
SuvorexantThe risk or severity of adverse effects can be increased when Pethidine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Pethidine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Pethidine is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Pethidine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Pethidine is combined with Tedizolid Phosphate.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Pethidine.
TelithromycinThe metabolism of Pethidine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pethidine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pethidine.
TerbinafineThe metabolism of Pethidine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrodotoxin.
ThalidomidePethidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pethidine.
TheobromineThe risk or severity of adverse effects can be increased when Pethidine is combined with Theobromine.
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
ThiamylalThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pethidine.
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
ThiopentalThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thioproperazine.
ThioridazineThioridazine may increase the hypotensive activities of Pethidine.
ThioridazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thioridazine.
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Pethidine.
ThiotepaThe metabolism of Pethidine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiagabine.
TiclopidineThe metabolism of Pethidine can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Pethidine is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pethidine.
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Pethidine.
TizanidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.
TocilizumabThe serum concentration of Pethidine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolcapone.
ToloxatoneToloxatone may increase the serotonergic activities of Pethidine.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pethidine.
TolvaptanThe risk or severity of adverse effects can be increased when Pethidine is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Pethidine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pethidine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pethidine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Pethidine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Pethidine.
TranylcypromineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tranylcypromine.
TrazodonePethidine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pethidine.
TriamtereneThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Pethidine is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Pethidine is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Pethidine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Pethidine.
TriflupromazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pethidine.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pethidine.
TrimipramineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pethidine.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pethidine.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pethidine.
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Pethidine.
UlaritideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Pethidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pethidine.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.
VenlafaxineThe metabolism of Pethidine can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Pethidine is combined with Venlafaxine.
VerapamilThe metabolism of Pethidine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Pethidine is combined with Vigabatrin.
VilazodonePethidine may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pethidine.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Pethidine.
VoriconazoleThe metabolism of Pethidine can be decreased when combined with Voriconazole.
VortioxetinePethidine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pethidine.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Pethidine.
XylazineThe risk or severity of adverse effects can be increased when Pethidine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Pethidine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziconotide.
ZimelidinePethidine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Pethidine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Pethidine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Pethidine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pethidine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pethidine.
ZonisamideThe risk or severity of adverse effects can be increased when Pethidine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Pethidine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Gene Name:
GRIN2A
Uniprot ID:
Q12879
Molecular Weight:
165281.215 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2C
Uniprot ID:
Q14957
Molecular Weight:
134207.77 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN2D
Uniprot ID:
O15399
Molecular Weight:
143750.685 Da
References
  1. Yamakura T, Sakimura K, Shimoji K: N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH. Anesth Analg. 2000 Apr;90(4):928-32. [PubMed:10735801 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Hustveit O: Binding of fentanyl and pethidine to muscarinic receptors in rat brain. Jpn J Pharmacol. 1994 Jan;64(1):57-9. [PubMed:8164394 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B: From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem. 2001 Oct 11;44(21):3378-90. [PubMed:11585443 ]
  2. Bryant, Bronwen (2010). Pharmacology for Health Professionals (Paperback) (3rd ed.). Chatswood: Mosby Australia. [ISBN:978-0-7295-3929-6 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Lomenzo SA, Izenwasser S, Gerdes RM, Katz JL, Kopajtic T, Trudell ML: Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3273-6. [PubMed:10612583 ]
  2. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  3. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  2. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binding
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML: Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem. 2005 Mar 10;48(5):1336-43. [PubMed:15743177 ]
  2. Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML: Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29. [PubMed:20980153 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6. [PubMed:15319333 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Edwards DJ, Svensson CK, Visco JP, Lalka D: Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet. 1982 Sep-Oct;7(5):421-33. [PubMed:6754208 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Edwards DJ, Svensson CK, Visco JP, Lalka D: Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet. 1982 Sep-Oct;7(5):421-33. [PubMed:6754208 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23